Clinical, biochemical and morphologic diagnostic markers in an infant male pseudohermaphrodite patient with compound heterozygous mutations (G115D/R246W) in SRD5A2 gene.
A patient with male pseudohermaphroditism and clinical diagnosis of partial androgen insensitivity in the neonatal period was studied at pubertal age for a molecular diagnosis. Hormone studies were conducted at baseline and under hCG stimulation for testosterone and dihydrotestosterone determinations at 2 months of age. Gonadectomy was performed at 4 months. At the age of 13 years genital skin fibroblasts were studied for androgen binding and 5alpha-reductase activity and peripheral blood DNA was available for androgen receptor (AR) and 5alpha-reductase (SRD5A2) gene analysis. Exons 1-8 of AR gene and exons 1-5 of SRD5A2 gene were sequenced. AR gene coding sequences were normal. SRD5A2 gene analysis revealed two heterozygote mutations (G115D and R246W), with the mother carrying the G115D and the father the R246W mutations. The compound heterozygote mutations in SRD5A2 gene explained an extremely low 5alpha-reductase enzyme activity in genital skin fibroblasts. Revision of hormonal data from the neonatal period revealed an increased testosterone-to-dihydrotestosterone ratio at the end of an hCG stimulation test, which concurred with the molecular diagnosis. Testis morphology at 4 months of age was normal. Clinical and biochemical differential diagnosis between partial androgen insensitivity syndrome and 5alpha-reductase enzyme deficiency is difficult in the neonatal period and before puberty. Our results show that in our patient the testosterone-to-dihydrotestosterone ratio would have adequately orientated the diagnosis. The two mutations in SRD5A2 gene have been described in patients of different lineages, though not in combination to date. Testis morphology showed that, during early infancy, the 5alpha-reductase deficiency may not have affected interstitial or tubular development.
Fernández-Cancio
Mónica
M
Unidad Investigación Endocrinología y Nutrición Pediátricas, Hospital Vall d'Hebron, Barcelona, España.
Rodó
Joan
J
Andaluz
Pilar
P
Martínez de Osaba
María Jesús
MJ
Rodríguez-Hierro
Francisco
F
Esteban
Cristina
C
Carrascosa
Antonio
A
Audí
Laura
L
D013741:3-Oxo-5-alpha-Steroid 4-Dehydrogenase / Q000172:deficiency* / Q000235:genetics*; D000293:Adolescent; D013734:Androgen-Insensitivity Syndrome / Q000175:diagnosis / Q000201:enzymology / Q000235:genetics; D001483:Base Sequence; D015415:Biomarkers / Q000097:blood; D004247:DNA / Q000235:genetics; D004252:DNA Mutational Analysis; D003937:Diagnosis, Differential; D013196:Dihydrotestosterone / Q000097:blood; D012734:Disorders of Sex Development / Q000175:diagnosis / Q000201:enzymology* / Q000235:genetics*; D005260:Female; D006579:Heterozygote; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D009154:Mutation; D010375:Pedigree; D013737:Testis / Q000473:pathology; D013739:Testosterone / Q000097:blood
D015415:Biomarkers; D013196:Dihydrotestosterone; D013739:Testosterone; D004247:DNA; D013741:3-Oxo-5-alpha-Steroid 4-Dehydrogenase